ClinicalTrials.gg
CompletedNCT00688740TAX316Updated Feb 16, 2011Results posted

Docetaxel in Node Positive Adjuvant Breast Cancer

A Phase 3 interventional study of Docetaxel and 5-fluorouracil in Breast Cancer, sponsored by Sanofi. Completed at 20 sites in 20 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-02-16.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,491
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
18th of 248
1,491 · median 68
Started
1997
with 4 others
Phase 3
51 of 264
5 open now
Registered
158th of 264
by date
Lead sponsor
6 of 264
Sanofi

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 18th largest by enrollment of the 248 interventional ones that give a count, is one of 5 that started in 1997, is one of 51 in phase 3, and was the 158th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study was to compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to 5-fluorouracil in combination with doxorubicin and cyclophosphamide in operable breast cancer patients with positive axillary lymph nodes.

Read the detailed description

In addition to the 5-year analysis conducted in September 2003, two other analyses were planned when 590 and 700 Disease Free Survival events occurred. However, due to the lower than predicted DFS event rate, and in agreement with FDA and EMA, a time-based final analysis at 10 years was considered more appropriate than an event-based (700 Disease Free Survival events) analysis.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • adjuvant treatment
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven breast cancer (invasive adenocarcinoma with at least one axillary lymph node showing evidence of tumor among a minimum of six resected lymph nodes).
  • Definitive surgical treatment must be either mastectomy, or breast conserving surgery with axillary lymph node dissection for operable breast cancer. Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma.

Exclusion criteria

Exclusion criteria:

  • Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).
  • Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,491 participants (actual)

Study arms

  • Experimental
    TAC (Docetaxel)

    docetaxel (75 mg/m\^2) in combination with doxorubicin (50 mg/m\^2) and cyclophosphamide (500 mg/m\^2) on day 1 every 3 weeks for 6 cycles of treatment

    Drug: Docetaxel · Drug: Doxorubicin · Drug: Cyclophosphamide

  • Active comparator
    FAC (5-fluorouracil)

    5-fluorouracil (500 mg/m\^2) in combination with doxorubicin (50 mg/m\^2) and cyclophosphamide (500 mg/m\^2) on day 1 every 3 weeks for 6 cycles of treatment

    Drug: 5-fluorouracil · Drug: Doxorubicin · Drug: Cyclophosphamide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Disease-Free Survival Events

    Disease-Free Survival (DFS)- are defined as local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first.

    Time frame: up to 10 year follow-up

Secondary outcomes

  1. Number of Participants With Overall Survival Events

    Overall Survival - time from the date of randomization up to the date of death of any cause.

    Time frame: up to 10 year follow-up

  2. Number of Participants With Second Primary Malignancies (Toxicity)

    Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast.

    Time frame: up to 10 year follow-up

07

Results

Posted Feb 14, 2011

Participant flow

Between June 1997 and June 1999, 1491 women from 20 countries were enrolled in the study. The last patient last visit occurred in January 2010.

Participant flow — Overall Study
MilestoneTAC (Docetaxel)FAC (5-fluorouracil)
Started745746
Completed679711
Not completed6635
Withdrew: Adverse event458
Withdrew: Death22
Withdrew: Lost to follow-up01
Withdrew: Consent withdrawn1717
Withdrew: Breast cancer relapse14
Withdrew: Violation of inclusion criteria13

Outcome measures

PrimaryNumber of Participants With Disease-Free Survival Events

Disease-Free Survival (DFS)- are defined as local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first.

Time frame:
up to 10 year follow-up
Reported as:
Number · Participants
Number of Participants With Disease-Free Survival Events
ParticipantsTAC (Docetaxel)FAC (5-fluorouracil)
Number of Participants With Disease-Free Survival Events287 (0.579 to 0.650)333 (0.513 to 0.586)
Statistical analysis
  • TAC (Docetaxel) vs FAC (5-fluorouracil) · Log Rank · p = 0.0043 (Pairwise stratified log-rank test on the number of positive axillary nodes as per randomization) · Cox proportional hazard: 0.795 · 95% CI 0.679 to 0.932
SecondaryNumber of Participants With Overall Survival Events

Overall Survival - time from the date of randomization up to the date of death of any cause.

Time frame:
up to 10 year follow-up
Reported as:
Number · Participants
Number of Participants With Overall Survival Events
ParticipantsTAC (Docetaxel)FAC (5-fluorouracil)
Number of Participants With Overall Survival Events188 (0.724 to 0.786)241 (0.651 to 0.719)
Statistical analysis
  • TAC (Docetaxel) vs FAC (5-fluorouracil) · Log Rank · p = 0.0020 (Pairwise stratified log-rank test on the number of positive axillary nodes as per randomization) · Cox proportional hazard: 0.742 · 95% CI 0.613 to 0.898
SecondaryNumber of Participants With Second Primary Malignancies (Toxicity)

Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast.

Time frame:
up to 10 year follow-up
Reported as:
Number · Participants
Number of Participants With Second Primary Malignancies (Toxicity)
ParticipantsTAC (Docetaxel)FAC (5-fluorouracil)
Number of Participants With Second Primary Malignancies (Toxicity)6766

Adverse events

Collected over from date of randomization until the completion of the 10-year follow-up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAC (Docetaxel)—267/744 (35.9%)744/744 (100%)
FAC (5-fluorouracil)—67/736 (9.1%)734/736 (99.7%)
Most frequent serious events
Showing 10 of 123
Most frequent serious events
EventTAC (Docetaxel)FAC (5-fluorouracil)
Fever in absence of infectionGeneral disorders187/74424/736
VomitingGastrointestinal disorders11/7446/736
NauseaGastrointestinal disorders8/7443/736
PharyngitisInfections and infestations7/7441/736
DiarrhoeaGastrointestinal disorders6/7441/736
PyrexiaGeneral disorders6/7442/736
StomatitisGastrointestinal disorders5/7440/736
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/7444/736
Deep vein thrombosisVascular disorders1/7444/736
PneumoniaInfections and infestations4/7442/736
Most frequent other events
Showing 10 of 57
Most frequent other events
EventTAC (Docetaxel)FAC (5-fluorouracil)
Any skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders734/744718/736
AlopeciaSkin and subcutaneous tissue disorders728/744715/736
Any gastrointestinal disordersGastrointestinal disorders713/744709/736
Any general disorders and administration site conditionsGeneral disorders673/744610/736
NauseaGastrointestinal disorders599/744647/736
AstheniaGeneral disorders592/744513/736
StomatitisGastrointestinal disorders508/744374/736
VomitingGastrointestinal disorders327/744436/736
Any nervous system disordersNervous system disorders427/744318/736
PainGeneral disorders312/744264/736

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TAC (Docetaxel)FAC (5-fluorouracil)Total
Between 18 and 65 years6977051402
>=65 years484189
Sex: Female, Male
Sex: Female, Male(Participants)TAC (Docetaxel)FAC (5-fluorouracil)Total
Female7457461491
Male000
Number of Positive Nodes
Number of Positive Nodes(participants)TAC (Docetaxel)FAC (5-fluorouracil)Total
1-3 Positive Nodes467459926
4 or More Positive Nodes278287565
08

Study locations

20 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • Sanofi-Aventis Administrative Office
    Wien, Austria
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Praha, Czech Republic
  • Sanofi-Aventis Administrative Office
    Cairo, Egypt
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Athens, Greece
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • sanofi-aventis Administrative office
    Natanya, Israel
  • Sanofi-Aventis Administrative Office
    Warszawa, Poland
  • Sanofi-Aventis Administrative Office
    Porto Salvo, Portugal
  • Sanofi-Aventis Administrative Office
    Bratislava, Slovakia
  • Sanofi-Aventis Administrative Office
    Midrand, South Africa
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-aventis adminsitrative office
    Guildford Surrey, United Kingdom
  • Sanofi-aventis administrative office
    Montevideo, Uruguay
09

References and documents

Publications

  • Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13. doi: 10.1056/NEJMoa043681. PubMed 15930421 ↗
  • Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodriguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houe V, Vogel C; TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan;14(1):72-80. doi: 10.1016/S1470-2045(12)70525-9. Epub 2012 Dec 12. PubMed 23246022 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 1997, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2008
First posted
Jun 3, 2008
Start
Jun 1997
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Feb 14, 2011
Last update
Feb 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00688740
Lead sponsor
Sanofi
Collaborators
Cancer International Research Group (CIRG)
First posted
Jun 3, 2008
Start date
Jun 1997
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Feb 14, 2011
Last update
Feb 16, 2011

Study contacts

ICD
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion